Healthcare Novartis to buy AveXis for $8.7 billion Updated : April 09, 2018 10:55 AM IST The Novartis offer represents a premium of 88% to AveXis’ closing price on April 6, 2018. AveXis' drug AVXS-101 granted orphan drug designation, approval and launch expected in 2019. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.